Abstracts

Neutralizing Antibody Protection: Where Do We Go From Here?

Presentation: The Antibody Mediated Prevention (AMP) trials did not demonstrate HIV prevention efficacy (PE) of the CD4-binding-site-targetting broadly neutralizing antibody (bnAb), VRC01 (10mg/kg or 30mg/kg IV vs. placebo). However, 75% PE was observed against viruses sensitive to VRC01 with an IC80 200 at the estimated time of exposure to a given exposing virus was associated…

Ruxolitinib-Mediated HIV-1 Reservoir Decay in A5336 Phase IIa Trial

Background: Ruxolitinib is FDA approved for myelofibrosis, polycythemia vera, atopic dermatitis and chronic graft-versus-host disease. We evaluated ruxolitinib’s impact on the peripheral HIV-1 reservoir and key immunomodulatory events driving HIV-1 persistence in people with HIV-1 (PWH) in an AIDS Clinical Trial (ACTG) sponsored open-label randomized Phase 2a multi-site trial (n=60). Methods: Inclusion criteria: ≥18 age…

Hazardous Alcohol Use Predicts Detectable Viremia Among Ugandan Women: A Prospective Analysis

Background: Hazardous alcohol use is associated with poor HIV care outcomes, including poor adherence to antiretroviral therapy (ART) and viral non-suppression. In Uganda, a setting with a generalized HIV epidemic, research has largely focused on understanding this relationship in men because they are more likely to engage in hazardous alcohol use. However, hazardous alcohol use…

Vaccine Effectiveness Against COVID In-Hospital Mortality by HIV Status Across SARS-CoV-2 Variants

Background: There is limited data on the impact of COVID-19 vaccines on mortality reduction among people living with HIV (PLHIV) across the different SARS-CoV-2 variant waves. We assessed the impact of COVID-19 vaccine in reducing in-hospital mortality among PLHIV relative to HIV negative population during the different SARS-CoV-2 variant waves. Methods: We analyzed individual-level data…

Incidence of Health Facility Switching and HIV Viral Rebound in Uganda: A Population-Based Study

Background: Prior studies have shown that a sizeable fraction of persons on antiretroviral therapy (ART) in Africa, once believed to be care-disengaged, have actually transferred to other healthcare facilities for continued HIV treatment. However, the relationship between facility switching and virologic outcomes, specifically HIV viral rebound, among persons on ART is poorly understood. Methods: We…

What Are the Outcomes for Established Clients Enrolled in DSD During the First 3 Years on ART?

Background: Replacing routine clinic visits with differentiated service delivery (DSD) models for HIV treatment could benefit DSD clients and the health system, but its value depends on maintaining or improving patient outcomes. South Africa’s DSD models include facility pick-up points, external pick-up points and adherence clubs, which facilitate easier access to medication. We conducted a…

Quantifying HIV-1 Transmission Between People Who Inject Drugs and Other Populations in Kenya

Background: Although recent modeling suggests needle-syringe programs have reduced parenteral HIV transmission among people who inject drugs (PWID) in Kenya, the prevalence in this population remains high (~14-20%, compared to ~4% in the larger population). Reducing transmission or acquisition requires understanding historic and modern transmission trends, but the relationship between the PWID HIV sub-epidemic and…

GIVE MOVE: Randomized Trial on Genotype-Informed Management of Viremia in Children and Adolescents

Background: Children and adolescents with HIV experience high rates of treatment failure. Genotypic resistance testing (GRT) to inform onward antiretroviral therapy (ART) is often inaccessible, and its effect on clinical outcomes in the context of viremia is unknown. Methods: The Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE) open-label randomized clinical trial enrolled children and…